Shorts: Moderna & Merck’s Personalized mRNA Melanoma Vaccine
For the first time, an mRNA cancer therapy has succeeded in a Phase 3 trial. Merck and Moderna's intismeran autogene — a vaccine built from a patient's own tumor mutations — improved recurrence-free and distant metastasis-free survival when added to Keytruda in high-risk melanoma. We look at why this result is being called a landmark, touch on how mRNA teaches the immune system to hunt cancer cells, and what comes next.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.